Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129414 | 1.00 | DRD4 (0.32) | DRD4 | |
| SCHEMBL14925923 | 1.00 | DRD4 (0.32) | DRD4 | |
| SCHEMBL14925920 | 1.00 | DRD4 (0.32) | DRD4 | |
| SCHEMBL24273692 | 0.83 | — | — | |
| SCHEMBL17173251 | 0.83 | — | — | |
| SCHEMBL2737379 | 0.81 | DRD4 (0.31) | DRD4 | |
| SCHEMBL2737431 | 0.81 | DRD4 (0.31) | DRD4 | |
| SCHEMBL22901100 | 0.81 | — | — | |
| SCHEMBL12966256 | 0.81 | — | — | |
| SCHEMBL2737237 | 0.81 | DRD4 (0.31) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| US-9193714-B2 | Fluorinated estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9187460-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-9078871-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140364427-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. | 2014-12-11 | — | — | US | disclosed |
| US-8853423-B2 | Indane estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8703810-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115037-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | DRD4 4274/4885 |
| US-20140364427-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | DRD4 4273/4885 |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | DRD4 4364/4885 |
| US-20150005286-A1 | FLUORINATED ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESRRG | DRD4 4075/4885 |
| US-20130150342-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | DRD4 1752/4885 |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | DRD4 4273/4885 |
| US-20130137746-A1 | INDANE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GPER1, ESR2, ESR1 | DRD4 4387/4885 |
| US-20160347742-A1 | HETEROCYCLIC ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, GPER1, ESRRG | DRD4 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.